SCHEMBL1684611

SCHEMBL1684611

Cc1ccn2c(-c3csc(Nc4ccc(I)cc4)n3)c(C)nc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.67
MAPT P10636 11/20 0.63
GAA P10253 9/20 0.63
KDM4E B2RXH2 8/20 0.63
LMNA P02545 7/20 0.63
ALDH1A1 P00352 7/20 0.63
HTT P42858 6/20 0.63
SMN1; SMN2 Q16637 6/20 0.63
MEN1 O00255 6/20 0.63
KMT2A Q03164 6/20 0.63
NPSR1 Q6W5P4 4/20 0.63
HPGD P15428 3/20 0.63
ALOX12 P18054 3/20 0.63
NR2F2 P24468 1/20 0.62
PRKD3 O94806 1/20 0.59
MAP4K4 O95819 1/20 0.59
PIM1 P11309 1/20 0.59
RPS6KB1 P23443 1/20 0.59
CDK2 P24941 1/20 0.59
FLT4 P35916 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL18040673 0.99 SYK (0.66) SYKMAPTGAAKDM4ELMNA
SCHEMBL1684593 0.92 MAPT (0.73) SYKMAPTGAAKDM4ELMNA
SCHEMBL1684920 0.89 SYK (0.67) SYKMAPTGAAKDM4ELMNA
SCHEMBL1684773 0.89 SYK (0.67) SYKMAPTGAAKDM4ELMNA
SCHEMBL1684431 0.89 PRKD3 (0.74) SYKMAPTGAAKDM4ELMNA
Bromide SCHEMBL18040699 0.88 SYK (0.66) SYKMAPTGAAKDM4ELMNA
Bromide SCHEMBL18040728 0.88 SYK (0.66) SYKMAPTGAAKDM4ELMNA
SCHEMBL1684392 0.87 SYK (0.64) SYKMAPTGAAKDM4ELMNA
SCHEMBL1684629 0.87 SYK (0.64) SYKMAPTGAAKDM4ELMNA
Bromide SCHEMBL18040752 0.86 MAPT (0.64) SYKMAPTGAAKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US disclosed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A SYK 3457/4885MAPT 4026/4885GAA 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.